AHA summary of Pfizer COVID-19 vaccine EUA
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
The summary covers dosing, storage and handling, preparation, and contraindications and adverse reactions. View the AHA Special Bulletin and review AHA resources on this and other COVID-19 vaccines and treatments.
Also over the weekend, the Centers for Disease Control and Prevention formally recommended the vaccine’s use for patients age 16 and older
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…